To identify immune strategies to restore CRC-NK functionality, we addressed different in vitro treatments, including the pre-incubation of tumor cells with cetuximab and NK cell stimulation with lenalidomide, IL-2, or IL-15. This evidence concerns the gene IL15 and neoplasm.